Eli Lilly and Company (LLY)vsTalkspace Inc (TALK)
LLY
Eli Lilly and Company
$1,183.46
+0.13%
HEALTHCARE · Cap: $1.03T
TALK
Talkspace Inc
$5.25
0.00%
HEALTHCARE · Cap: $868.92M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 32320% more annual revenue ($79.67B vs $245.73M). LLY leads profitability with a 33.5% profit margin vs 0.1%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
TALK
Hold40
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Earnings expanding 181.1% YoY
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.1x book value
Smaller company, higher risk/reward
ROE of 1.0% — below average capital efficiency
0.1% margin — thin
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : TALK
The strongest argument for TALK centers on EPS Growth, Altman Z-Score. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : TALK
The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while TALK is a value play — different risk/reward profiles.
TALK carries more volatility with a beta of 1.12 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 40/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Talkspace Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?